9 results found.

Leukodystrophy, Metachromatic, Hereditary Central Nervous System Clinical Trial using Natural History Study of Children With Metachromatic Leukodystrophy

Shire - Recruiting N/A to 12 years.
- Natural History Study of Children With Metachromatic Leukodystrophy.
Natural History Study of Children With Metachromatic Leukodystrophy

Urticaria, Arthropathy, Lymphadenopathy, or Nervous System Anomal Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 years or older.
- Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases).

Parkinson Disease, Autonomic Nervous System Diseases, or Pure Aut Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Biomarkers of Risk of Parkinson Disease.

Primary Progressive Multiple Sclerosis,, Secondary Progressive Mu Clinical Trial using Combined program; Physiotherapy in private practice

Assistance Publique - H“pitaux de Paris - Recruiting 18 years to 80 years.
- A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis..
Combined program; Physiotherapy in private practice

Central Nervous System Disease, or Multiple Sclerosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the CNS.

Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Se Clinical Trial using Tcelna; Placebo

Opexa Therapeutics, Inc. - Recruiting 18 years to 60 years.
- A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis.
Tcelna; Placebo

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous Syst Clinical Trial using NEUROSTEMr-AD

Samsung Medical Center - Recruiting 50 years to 75 years.
- The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostemr-AD.
NEUROSTEMr-AD

Central Nervous System Disorder, Spinal Diseases, or Peripheral N Clinical Trial

University of California, Irvine - Recruiting 7 years or older.
- Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database.

Autoimmune Diseases, Immune System Diseases, Demyelinating Diseas Clinical Trial using Autologous mesenchymal stem cells from adipose tissue.

Fundaci¢n P£blica Andaluza Progreso y Salud - Recruiting 18 years or older.
- Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment.
Autologous mesenchymal stem cells from adipose tissue.